Editas Medicine’s (EDIT) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reissued their buy rating on shares of Editas Medicine (NASDAQ:EDIT) in a research report report published on Monday morning,Benzinga reports. They currently have a $3.50 target price on the stock.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Editas Medicine in a research note on Wednesday, January 21st. TD Cowen reissued a “buy” rating on shares of Editas Medicine in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $4.63.

Editas Medicine Stock Up 16.0%

Shares of EDIT opened at $2.32 on Monday. The business has a fifty day moving average of $2.01 and a 200 day moving average of $2.57. The company has a market cap of $226.48 million, a PE ratio of -0.97 and a beta of 2.16. Editas Medicine has a 52-week low of $0.91 and a 52-week high of $4.54.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings data on Wednesday, March 11th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.21. Editas Medicine had a negative net margin of 430.84% and a negative return on equity of 277.29%. The business had revenue of $24.74 million for the quarter, compared to analysts’ expectations of $8.77 million. As a group, research analysts anticipate that Editas Medicine will post -2.71 earnings per share for the current fiscal year.

Institutional Trading of Editas Medicine

Several institutional investors and hedge funds have recently made changes to their positions in the business. Captrust Financial Advisors purchased a new stake in shares of Editas Medicine during the second quarter valued at $26,000. StoneX Group Inc. purchased a new position in Editas Medicine in the 4th quarter worth about $33,000. Victory Capital Management Inc. purchased a new position in Editas Medicine in the 3rd quarter worth about $36,000. Sei Investments Co. bought a new stake in Editas Medicine during the 3rd quarter valued at about $46,000. Finally, Baader Bank Aktiengesellschaft bought a new stake in Editas Medicine during the 3rd quarter valued at about $50,000. 71.90% of the stock is currently owned by institutional investors.

Key Headlines Impacting Editas Medicine

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: Q4 results beat expectations — EPS loss of $0.06 vs. consensus -$0.27 and revenue of $24.7M vs. ~$8.8M consensus, showing a narrower loss and a material revenue upside. This is the primary near-term catalyst lifting the stock. Editas Q4 and Business Update
• Positive Sentiment: Pipeline and operational updates: lead candidate EDIT-401 showed >90% mean LDL-C reduction in preclinical work and remains on track for IND/CTA submission mid‑2026, with first-in-human data targeted by year-end 2026 — positive clinical-readout timing for future value creation. The company also says cash runway extends into Q3 2027. GlobeNewswire: Q4 Results & Business Updates
• Positive Sentiment: Analyst support: Chardan Capital reaffirmed a “buy” rating and set a $3.50 price target, implying meaningful upside from current levels and lending third‑party validation to recent results. Benzinga: Chardan Reaffirms Buy
• Neutral Sentiment: Short-interest report in the feed is effectively non-informative (shows 0 shares / 0 days), so no clear short-squeeze signal is evident from that data point.
• Negative Sentiment: Company remains unprofitable with negative net margin and ROE (reported metrics are large negatives), and analysts still model deeper FY losses; Editas is early‑stage and dependent on future clinical milestones to justify valuation — risk of binary clinical/operational outcomes persists. Quarterly Report / Press Release

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.